NeoStem, Inc. has entered agreements with the University of California, San Francisco and the labs of Jeffrey Bluestone, Ph.D., and Qizhi Tang, Ph.D., for the development of human Regulatory T cells (Tregs) for the treatment of type 1 diabetes, steroid resistant asthma, and organ transplant rejection.
NeoStem will manufacture a Treg product for a Phase II trial to treat patients newly diagnosed with type 1 diabetes and will collaborate with Dr. Bluestone on allo-specific Tregs for organ transplant tolerance in another Phase II study. Also, NeoStem plans to sponsor a Phase Ia/IIb study on the use of Tregs for the treatment of steroid resistant asthma.
"Worldwide, type 1 diabetes affects over 340 million people, and has an economic cost of over $174 billion in the U.S. alone. Severe asthma affects another 60 million people," said Dr. Robin L. Smith, chairman and chief executive officer of NeoStem. "Our collaboration with Drs. Bluestone and Tang, industry leaders in Treg research, and UCSF represents a significant advance in the development of our Athelos technology platform."